Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Recent & Breaking News (OTCPK:ARLZQ)

IIROC Trading Halt - ARZ

Canada NewsWire August 10, 2018

Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets

PR Newswire August 10, 2018

Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders

PR Newswire June 29, 2018

Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement

PR Newswire June 29, 2018

Aralez Announces First Quarter 2018 Financial Results

PR Newswire May 8, 2018

Aralez Announces New Strategic Direction

PR Newswire May 8, 2018

Aralez To Announce First Quarter 2018 Results On May 8, 2018

PR Newswire April 27, 2018

Eyenovia Appoints Three Industry Veterans to Board of Directors

GlobeNewswire March 26, 2018

Aralez Pharmaceuticals Inc. to Host Earnings Call

Accesswire March 13, 2018

Select Sands Appoints Mr. Daniel Gillett and Mr. Steven Goldman to the Board of Directors

GlobeNewswire March 6, 2018

Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018

PR Newswire March 6, 2018

Aralez to Present at the 2018 BIO CEO and Investor Conference

PR Newswire January 30, 2018

Aralez Announces Departure of Chief Financial Officer

PR Newswire November 30, 2017

Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter

PR Newswire November 9, 2017

Aralez To Report Third Quarter 2017 Financial Results On November 9, 2017

PR Newswire October 25, 2017

Recent Developments in the Pharmaceutical Industry

PR Newswire September 5, 2017

Biotech Stock Performance Review -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and Aviragen Therapeutics

PR Newswire August 16, 2017

Aralez Reports Second Quarter 2017 Financial Results

PR Newswire August 9, 2017

Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017

PR Newswire July 24, 2017

Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents

PR Newswire June 27, 2017